<DOC>
<DOCNO>EP-0614911</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Compounds having a sulfonamide and an amidinegroup, process for preparation and pharmaceutical compositions comprising them
</INVENTION-TITLE>
<CLASSIFICATIONS>C07K100	A61P900	A61K3116	C07D21500	A61P900	C07K506	C07K5065	A61K3116	C07K500	A61K31155	A61K31155	C07C31100	A61K3118	A61K3800	A61K3800	A61P2500	C07C31118	C07K5078	A61K3118	C07K1113	C07D21536	A61P2500	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07K	A61P	A61K	C07D	A61P	C07K	C07K	A61K	C07K	A61K	A61K	C07C	A61K	A61K	A61K	A61P	C07C	C07K	A61K	C07K	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07K1	A61P9	A61K31	C07D215	A61P9	C07K5	C07K5	A61K31	C07K5	A61K31	A61K31	C07C311	A61K31	A61K38	A61K38	A61P25	C07C311	C07K5	A61K31	C07K1	C07D215	A61P25	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The subject of the invention is compounds of formula I 
<
IMAGE
>
  in which   Ar1 represents optionally substituted naphthyl, phenyl, quinolyl or isoquinolyl;   Ar2 represents optionally substituted phenyl or thienyl; R1, R2 and R'2 represent, independently of each other, H, (C1-C4)alkyl or R1 represents nothing and N is linked to Ar2 and, optionally, R2 and R'2 form a double bond,   or R1 or R2 is linked to Ar2 and represents (C1-C3)alkylene; R3 and R4, which are identical or different, represent H, (C1-C4)alkyl or form with the nitrogen atom to which they are attached a saturated (C5-C7)heterocycle;   Z1 represents (C1-C12)alkylene; Q1 represents methyl, amino, (C1-C4)alkoxycarbonylamino, (C1-C4)alkylamino, di(C1-C4)alkylamino, pyrrolidinyl, piperidino, morpholino, piperazinyl, 4-(C1-C4)alkyl piperazinyl, amidino, (C1-C4)alkylamidino, guanidino, (C1-C4)alkylguanidino, pyridyl, imidazolyl, pyrimidinyl, indolyl, hydroxyl, (C1-C4)alkoxy, (C2-C8)alkoxycarbonyl, amino(C1-C4)alkyl-N-(C1-C4)alkylamino, carbamoyl or phenyl which is optionally substituted;   Q2 represents H or (C1-C4)alkyl; Q3 represents H or (C1-C4)alkyl or Q1 and Q3 are linked to form a heterocycle and represent together (C2-C3)alkylene whereas Z1 represents nothing, in the form of pure enantiomers or of mixtures thereof in any proportions,  as well as their salts with acids. These compounds have an affinity for the biological receptors of neuropeptide Y (NPY) which are present in the central and peripheral nervous systems.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI SA
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CHRISTOPHE BERNARD
</INVENTOR-NAME>
<INVENTOR-NAME>
FOULON LOIC
</INVENTOR-NAME>
<INVENTOR-NAME>
PELLET ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
SERRADEIL-LE-GAL CLAUDINE
</INVENTOR-NAME>
<INVENTOR-NAME>
VALETTE GERARD
</INVENTOR-NAME>
<INVENTOR-NAME>
CHRISTOPHE, BERNARD
</INVENTOR-NAME>
<INVENTOR-NAME>
FOULON, LOIC
</INVENTOR-NAME>
<INVENTOR-NAME>
PELLET, ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
SERRADEIL-LE-GAL, CLAUDINE
</INVENTOR-NAME>
<INVENTOR-NAME>
VALETTE, GERARD
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Compounds of formula I


wherein

Ar
1
 represents naphthyl, phenyl, quinolyl or isoquinolyl
optionally substituted by Cl, F, (C
1-4
)alkyl, (C
1-4
)alkoxy,
hydroxyl or (C
1-4
)dialkylamino,
Ar
2
 denotes phenyl or thienyl, optionally substituted by
Cl, F, (C
1-4
)alkyl, (C
1-4
)alkoxy or hydroxyl;
R
1
, R
2
 and R'
2
 independently of one another denote H,
(C
1-4
)alkyl or R
1
 represents nothing and N is linked to
Ar
2
 and, optionally, R
2
 and R'
2
 form a double bond,
or R
1
 or R
2
 is linked to Ar
2
 and denotes (C
1-3
)alkylene;
R
3
 and R
4
, which may be identical or different, represent
H, (C
1-4
)alkyl or, together with the nitrogen atom to
which they are linked, form a (C
5-7
) saturated
heterocyclic group selected from pyrrolidine, piperidine

and hexahydroazepine;
Z
1
 represents (C
1-12
)alkylene optionally interrupted or
prolonged by (C
5-7
)cycloalkyl or phenyl;
Q
1
 denotes methyl, amino, (C
1-4
)alkoxycarbonylamino,
(C
1-4
)alkylamino, di(C
1-4
)alkylamino, pyrrolidinyl,
piperidino, morpholino, piperazinyl, (C
1-4
)alkyl-4-piperazinyl, 
amidino, (C
1-4
)alkylamidino, guanidino,
(C
1-4
)alkylguanidino, pyridyl, imidazolyl, pyrimidinyl,
indolyl, hydroxy, (C
1-4
)alkoxy, (C
2-8
)alkoxycarbonyl, amino
(C
1-4
)alkyl-N-(C
1-4
)alkylamino, carbamoyl or phenyl
optionally substituted by Cl, F, (C
1-4
)alkyl, (C
1-4
)alkoxy
or hydroxyl;
Q
2
 denotes H or (C
1-4
)alkyl;
Q
3
 denotes H or (C
1-4
)alkyl or Q
1
 and Q
3
 are linked to form
a heterocyclic group and together represent (C
2-3
)alkylene,
whereas Z
1
 represents nothing, in the form of
pure enantiomers or mixtures thereof in any desired

proportions,
and the salts thereof with acids.
Compounds according to claim 1 of formula I wherein

NR
3
R
4
 denotes pyrrolidinyl.
Compounds according to one of claims 1 and 2 of
formula I wherein Z
1
 denotes (C
4-9
)alkylene and
Q
1
 comprises a nitrogen atom fixed to Z
1
.
Compounds according to clam 3, wherein Q
1
 denotes an
amino, guanidino, amidino, (C
1-4
)alkoxycarbonylamino,
(C
1-4
)alkylamino, di(C
1-4
)alkylamino, (C
1-4
)alkylamidino,
guanidino, (C
1-4
)alkylguanidino, amino (C
1-4
)alkyl-N-(C
1-4
)alkylamino.
Process for preparing compounds of formula I
according to claim 1, characterised in that the nitrile

of formula II:

 
wherein Ar
1
, R
1
, R
2
, Ar
2
, R'
2
, R
3
 and R
4
 are as defined in
claim 1, in the form of a pure enantiomer or a mixture

of isomers in any desired proportions, is reacted with
an alcohol ROH in an acid medium to obtain an

intermediate imidoester, which is reacted with the amine
of formula



wherein Z
1
, Q
1
, Q
2
 have the same meanings as in formula
I.
Pharmaceutical composition containing a
therapeutically active dose of a compound of formula I

according to one of claims 1 to 3, in the form of pure
enantiomers or a mixture of enantiomers or a

pharmaceutically acceptable salt thereof combined with
at least one excipient.
Compounds according to claim 1 of formula I wherein

Ar
1
 represents naphthyl or phenyl optionally substituted
by Cl, F, (C
1-3
)alkyl or (C
1-3
)alkoxy;
Ar
2
 denotes phenyl optionally substituted by Cl, F, (C
1-3
)alkyl
or (C
1-3
)alkoxy;
R
1
, R
2
 and R'
2
 independently of one another denote H,
(C
1-4
)alkyl or R
1
 represents nothing and N is linked to
Ar
2
 and, optionally, R
2
 and R'
2
 form a double bond,
or R
1
 or R
2
 is linked to Ar
2
 and denotes (C
1-2
)alkylene; 
R
3
 and R
4
, which may be identical or different, represent
H, (C
1-4
)alkyl or, together with the nitrogen atom to
which they are linked, form a saturated heterocyclic

group selected from pyrrolidine and piperidine;
Z
1
 represents (C
1-12
)alkylene optionally interrupted or
prolonged by (C
5-7
)cycloalkyl or phenyl;
Q
1
 denotes methyl, amino, (C
1-4
)alkoxycarbonylamino,
(C
1-4
)alkylamino, di(C
1-4
)alkylamino, pyrrolidinyl,
piperidino, morpholino, piperazinyl, (C
1-4
)alkyl-4-piperazinyl,
amidino, (C
1-4
)alkylamidino, guanidino,
(C
1-4
)alkylguanidino, pyridyl, imidazolyl, pyrimidinyl,
hydroxy, (C
1-7
)alkoxy, (C
2-8
)alkoxycarbonyl, amino (C
1-4
)alkyl-N-(C
1-4
)alkylamino,
carbamoyl or phenyl optionally

substituted by Cl, F, (C
1-3
)alkyl or (C
1-3
)alkoxy;
Q
2
 denotes H or (C
1-4
)alkyl;
Q
3
 denotes H or (C
1-4
) alkyl or Q
1
 and Q
3
 are linked to form
a heterocyclic group and together represent

(C
2-3
)alkylene, whereas Z
1
 represents nothing, in the form
of pure enantiomers or a mixture thereof in any desired

proportions,
and the salt thereof with an acid.
</CLAIMS>
</TEXT>
</DOC>
